Overview
- The European Commission granted EU-wide marketing authorization on September 17 following a positive assessment from the European Medicines Agency.
- Zurzuvae contains the active ingredient zuranolone and is manufactured by Biogen.
- Regulators say symptoms can improve within about two weeks, noting standard antidepressants often act too slowly for this condition.
- The medicine is prescription-only and can cause side effects, according to reporting based on regulatory information.
- Postnatal mental health problems are common, with postpartum depression estimated to affect roughly 10–15% of mothers in Germany.